The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart

Completed · Phase 2 · Has a placebo group

Conditions studied: Ventricular Function

In brief

The purpose of this study is to determine whether an investigational drug (Alagebrium (generic: ALT-711), a type of medication referred to as an advanced glycaton end-product clever) can be combined with exercise training to reverse the stiffening of the heart that takes place naturally with aging.

Key facts

Study ID

NCT01014572

Run by

University of Texas Southwestern Medical Center

People needed

62

Starts

2008-07-01

Expected to finish

2013-12-01

Last updated by the study team

2020-08-07

Who can join

Age: 65 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy senior status (age > 64)
• Body mass index < 30
• Sedentary status (not exercising > 2/wk)

You may not qualify if…

• Hypertension
• Diabetes
• Heart Failure
• Asthma
• Chronic obstructive pulmonary disease
• Coronary artery disease (as evidenced by angina or prior myocardial infarction)
• Cerebrovascular disease (as evidenced by prior transient ischemic attack or stroke)

Where it is running

• The Institute for Exercise and Environmental Medicine — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.